PremiumThe FlyLantern Pharma secures FDA clearance for planned Phase 1b/2 trial of LP-184 Claritev, Lantern form strategic partnership for surgical cost transparency Lantern Pharma receives FDA clearance for LP-184 IND application PremiumThe FlyLantern Pharma reports Q4 EPS (54c) vs (39c) last year LTRN Earnings Report this Week: Is It a Buy, Ahead of Earnings? Biotech Alert: Searches spiking for these stocks today PremiumCompany AnnouncementsLantern Pharma Discusses Q3 Financial Results Webinar Lantern Pharma Advances AI-Driven Cancer Therapies Lantern Pharma reports Q3 EPS (42c), one estimate (56c)